Interventions to treat cutaneous leishmaniasis in children: A systematic review

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Chagas disease 1 infectiousdiseases
cutaneous leishmaniasis 13 infectiousdiseases
paromomycin 1 infectiousdiseasesdrugs
pentamidine 1 infectiousdiseasesdrugs
visceral leishmaniasis 2 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
paromomycin 37535 excluded studies that did not report outcomes for patients aged <12 years, showed higher efficacy of paromomycin in patients <18 years of age[[28]]. This intervention was found to have good evidence in previous systematic
pentamidine 16967 criteria:1) Previous treatment with antimonials, ketoconazole or another imidazole, amphotericin B or pentamidine ; 2) mucosal leishmaniasis; 3) severe cardiovascular, renal, hepatic, or pancreatic disease; 4) pregnant
Select Disease Character Offset Disease Term Instance
Chagas disease 39606 dosing of miltefosine for visceral leishmaniasis (NCT02431143), and the dosing of benznidazole for Chagas disease [[36]].Importantly, this review also highlights the lack of data regarding treatments in patients less
cutaneous leishmaniasis 62 Title: PLoS Neglected Tropical DiseasesInterventions to treat cutaneous leishmaniasis in children: A systematic reviewAlternative Title: Interventions for CL in Children: a reviewAndrés
cutaneous leishmaniasis 1471 (epub): 12/2018Publication date (collection): 12/2018AbstractBackgroundCase management in children with cutaneous leishmaniasis (CL) is mainly based on studies performed in adults. We aimed to determine the efficacy and harms of
cutaneous leishmaniasis 6747 CRD42017062164. The PICO question[[15]] covered a population of pediatric patients with confirmed diagnosis of cutaneous leishmaniasis without mucosal or visceral involvement; intervention with systemic and local treatments for cutaneous
cutaneous leishmaniasis 6864 leishmaniasis without mucosal or visceral involvement; intervention with systemic and local treatments for cutaneous leishmaniasis ; comparison group with placebo, active drug or local treatments. The outcomes of interest for this review
cutaneous leishmaniasis 7242 and non-randomized (cohort) studies.Inclusion criteria: Original articles that assess treatments of cutaneous leishmaniasis including pediatric patients (≤12 years of age), with no restrictions regarding ethnicity, country,
cutaneous leishmaniasis 7464 country, sex, or year of publication.Exclusion criteria were: 1) articles assessing a disease other than cutaneous leishmaniasis (e.g. mucosal or muco-cutaneous leishmaniasis, visceral leishmaniasis); 2) publication language other
cutaneous leishmaniasis 7510 criteria were: 1) articles assessing a disease other than cutaneous leishmaniasis (e.g. mucosal or muco- cutaneous leishmaniasis , visceral leishmaniasis); 2) publication language other than English, Spanish or Portuguese; 3) case
cutaneous leishmaniasis 8551 National Institutes of Health) and Google Scholar for gray literature. The search terms used were “ cutaneous leishmaniasis ”; “treatment”, “therapy”, “management”; “outcome”, “cure” or “failure”; and
cutaneous leishmaniasis 9642 search of references included in previously published major systematic reviews of interventions for cutaneous leishmaniasis [[16]–[18]] was performed (by AUR) in order to find relevant references that were not captured in
cutaneous leishmaniasis 29086 variable (<18, <15, <12 or <10 years old).Interventions evaluated and outcomes of treatmentAmerican cutaneous leishmaniasis Miltefosine: Efficacy was assessed in a total of 130 pediatric patients from four studies conducted in
cutaneous leishmaniasis 32075 substantially lower efficacy in children <5 years of age (p<0.03 for all the comparisons)[[7]].Old-World cutaneous leishmaniasis Meglumine antimoniate: In total, 95 pediatric patients were included for assessment of this intervention.
cutaneous leishmaniasis 35677 presents a summary of evidence on efficacy and safety for treatments in pediatric populations with cutaneous leishmaniasis . It also provides evidence of the gaps in reporting of treatment outcomes for pediatric patients, even
cutaneous leishmaniasis 37224 including different length of follow-up. One clinical trial [[26]] showed that in Iranian children with cutaneous leishmaniasis , intralesional meglumine antimoniate had greater efficacy than cryotherapy (72.3% vs 41.7%, respectively).
visceral leishmaniasis 7535 assessing a disease other than cutaneous leishmaniasis (e.g. mucosal or muco-cutaneous leishmaniasis, visceral leishmaniasis ); 2) publication language other than English, Spanish or Portuguese; 3) case reports, case series, case-control
visceral leishmaniasis 39533 available drugs for CL and other NTDs. Some examples include the allometric dosing of miltefosine for visceral leishmaniasis (NCT02431143), and the dosing of benznidazole for Chagas disease[[36]].Importantly, this review also

You must be authorized to submit a review.